Eye Implants Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Observation of the Curative Effect of the Dexamethasone Vitreous Cavity Implant for the Treatment of Irvine-Gass Syndrome
CONCLUSION: The dexamethasone vitreous cavity implant (Ozurdex) is a safe and effective treatment, which can effectively improve patient's visual acuity and reduce macular edema associated with cataract surgery.PMID:37711084 | DOI:10.3967/bes2023.084 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - September 15, 2023 Category: Biomedical Science Authors: Yu Mao Li Qin Gao Li Yun Jia Si Meng Hou Yuan Yuan Xiao Xi Wen Ji Shuang Wang Source Type: research

Anterior segment complications after dexamethasone implantations:real world data
ConclusionThis study is the first long-term follow-up study in our country evaluating the safety of dexamethasone implant injections in various retinal diseases and presenting the first real world data. Cataract progression and increased IOP were found to be the most common side effects. We observed that the patient ’s diagnosis did not cause a statistically significant change in the observation of side effects. As a result of our findings, close follow-up of IOP after the injection of dexamethasone implants would be appropriate. (Source: International Ophthalmology)
Source: International Ophthalmology - September 14, 2023 Category: Opthalmology Source Type: research

Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study
ConclusionsIn DME eyes who did not sufficiently respond to previous therapies, the FAc-i was associated with an improvement in visual and anatomic outcomes. There were no unexpected adverse-events.Trial registration numberEudraCT identifier: 2016-001680-37. (Source: International Ophthalmology)
Source: International Ophthalmology - September 12, 2023 Category: Opthalmology Source Type: research

Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months
ConclusionThe FAc implant is safe and effective at treating NIU over 12 months in a real-world setting in Spain. (Source: International Ophthalmology)
Source: International Ophthalmology - September 12, 2023 Category: Opthalmology Source Type: research

Treatment discontinuation patterns of anti-vascular endothelial growth factor in retinal vein occlusion
CONCLUSION: Over 7.5 years, treatment was discontinued for three-quarters of RVOs. Stable disease was the most common reason for discontinuation, with nearly half (45%) of all RVOs in the cohort stable off active therapy. Better visual outcomes were achieved in BRVO than in CRVO, although both groups benefited from treatment.PMID:37669742 | DOI:10.1016/j.jcjo.2023.08.005 (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - September 5, 2023 Category: Opthalmology Authors: Amy Basilious Julie Duncan Bobbi Smuck Monali S Malvankar-Mehta Verena R Juncal Phil Hooper Tom G Sheidow Source Type: research